JAZZ
Jazz Pharmaceuticals plc
$240.20
+0.50%
$15.0B
No data for this timeframe.
Vol
Market Cap$15.0B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (92%)
Insider Activity0B / 5S
Insider Net $-$3.0M
SEC Reports9
Recent Activity
Aug 25, 2026
fda_pdufa
PDUFA: JAZZ — zanidatamab in HER2+ 1L advanced gastroesophageal adenocarcinoma — 2026-08-25
FDA target action date 2026-08-25 for JAZZ (Jazz Pharmaceuticals plc). Drug: zanidatamab. Indication
May 1, 2026
SEC
Bruce C. Cozadd, an officer at Jazz Pharmaceuticals, filed a Form 144 indicating intent to sell 6,000 shares of common s
144 — Impact 2/10
May 1, 2026
Insider
COZADD BRUCE C sold 6,000 shares
Director @ $203.33 ($1.2M)
Apr 24, 2026
SEC
This is an amended 10-K filing for Jazz Pharmaceuticals that primarily updates Part III to include proxy statement infor
10-K/A — Impact 4/10
Apr 1, 2026
SEC
Bruce Cozadd, CEO of Jazz Pharmaceuticals, filed a Form 144 to propose the sale of 6,000 shares worth approximately $1.1
144 — Impact 3/10
Apr 1, 2026
Insider
COZADD BRUCE C sold 3,684 shares
Director @ $190.22 ($700.8K)
Mar 9, 2026
Insider
Carr Patricia sold 1,287 shares
SVP, Chief Accounting Officer @ $182.94 ($235.4K)
Jun 15, 2020
Event
ZEPZELCA
Price Targets
$249.67
+3.9% upside
Hold
Current $240.20
Low $196.00
Median $247.50
High $307.00
18 analysts
$196.00
$307.00
Analyst Ratings
8Strong Buy
14Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 19, 2026 | UBS | UPGRADE | Neutral → Buy |
| May 6, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
| May 6, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 6, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| May 6, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $6.17 ▲ +2.1% | $5.53 — $7.07 | 175% YoY | 16 |
| Next Q | $6.36 ▼ -0.9% | $5.85 — $6.71 | -22% YoY | 16 |
| Current FY | $25.22 ▲ +4.4% | $24.38 — $26.99 | 201% YoY | 14 |
| Next FY | $25.55 ▲ +1.6% | $22.53 — $30.25 | 1% YoY | 16 |
Latest Reports
NEUTRAL
144
2/10
Bruce C. Cozadd, an officer at Jazz Pharmaceuticals, filed a Form 144 indicating intent to sell 6,000 shares of common s
May 1, 2026
NEUTRAL
10-K/A
4/10
This is an amended 10-K filing for Jazz Pharmaceuticals that primarily updates Part III to include proxy statement infor
Apr 24, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 1, 2026 | COZADD BRUCE | SELL | $1.2M |
| Apr 1, 2026 | COZADD BRUCE | SELL | $700.8K |
| Mar 9, 2026 | Carr Patricia | SELL | $235.4K |
| Mar 5, 2026 | Pearce Samantha | F | $472.3K |
| Mar 5, 2026 | Johnson Philip | F | $493.4K |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
10 unique insiders with 5 transactions. Net insider value: -$3.0M ($0.00 bought, $3.0M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 1, 2026 | COZADD BRUCE C | Director | SELL | 6,000 | $203.33 | $1.2M |
| Apr 1, 2026 | COZADD BRUCE C | Director | SELL | 3,684 | $190.22 | $700.8K |
| Mar 9, 2026 | Carr Patricia | SVP, Chief Accounting Officer | SELL | 1,287 | $182.94 | $235.4K |
| Mar 5, 2026 | Pearce Samantha | EVP, Chief Commercial Officer | F | 2,503 | $188.69 | $472.3K |
| Mar 5, 2026 | Johnson Philip L | EVP & Chief Financial Officer | F | 2,615 | $188.69 | $493.4K |
| Mar 5, 2026 | COZADD BRUCE C | Director | F | 15,114 | $188.69 | $2.9M |
| Mar 5, 2026 | Patil Neena M | EVP & Chief Legal Officer | F | 5,000 | $188.69 | $943.5K |
| Mar 5, 2026 | GALA RENEE D | President & CEO | F | 7,065 | $188.69 | $1.3M |
| Mar 5, 2026 | Carr Patricia | SVP, Chief Accounting Officer | F | 1,436 | $186.77 | $268.2K |
| Mar 5, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | F | 1,394 | $186.75 | $260.3K |
| Mar 5, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | F | 6,209 | $188.69 | $1.2M |
| Mar 3, 2026 | COZADD BRUCE C | Director | SELL | 3,159 | $186.09 | $587.8K |
| Feb 27, 2026 | RIEDEL NORBERT G | Director | M | 3,415 | $138.08 | $471.5K |
| Feb 27, 2026 | RIEDEL NORBERT G | Director | M | 3,415 | $0.00 | $0.00 |
| Feb 27, 2026 | Carr Patricia | SVP, Chief Accounting Officer | SELL | 1,117 | $190.91 | $213.2K |
| Feb 26, 2026 | Pearce Samantha | EVP, Chief Commercial Officer | A | 9,782 | $0.00 | $0.00 |
| Feb 26, 2026 | Patil Neena M | EVP & Chief Legal Officer | M | 20,125 | $113.10 | $2.3M |
| Feb 26, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | A | 14,822 | $0.00 | $0.00 |
| Feb 26, 2026 | LOVE TED W | Director | A | 1,527 | $0.00 | $0.00 |
| Feb 26, 2026 | GALA RENEE D | President & CEO | A | 44,465 | $0.00 | $0.00 |
| Feb 26, 2026 | Johnson Philip L | EVP & Chief Financial Officer | A | 11,857 | $0.00 | $0.00 |
| Feb 26, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | A | 4,447 | $0.00 | $0.00 |
| Feb 26, 2026 | Carr Patricia | SVP, Chief Accounting Officer | A | 2,223 | $0.00 | $0.00 |
| Feb 26, 2026 | Patil Neena M | EVP & Chief Legal Officer | M | 875 | $0.00 | $0.00 |
| Feb 26, 2026 | Patil Neena M | EVP & Chief Legal Officer | M | 20,125 | $0.00 | $0.00 |
9 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 8 neutral. Avg impact: 3.8/10.
NEUTRAL
144
2/10
Bruce C. Cozadd, an officer at Jazz Pharmaceuticals, filed a Form 144 indicating intent to sell 6,00
May 1, 2026
NEUTRAL
10-K/A
4/10
This is an amended 10-K filing for Jazz Pharmaceuticals that primarily updates Part III to include p
Apr 24, 2026
NEUTRAL
144
3/10
Bruce Cozadd, CEO of Jazz Pharmaceuticals, filed a Form 144 to propose the sale of 6,000 shares wort
Apr 1, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider transactions at Jazz Pharmaceuticals over the past week includes one open-marke
Mar 9, 2026
NEUTRAL
CLUSTER
3/10
A cluster of insider transactions at Jazz Pharmaceuticals over the past week includes one open-marke
Mar 9, 2026
NEUTRAL
CLUSTER
4/10
A cluster of insider transactions at Jazz Pharmaceuticals over the past week includes one open-marke
Mar 9, 2026
NEUTRAL
CLUSTER
4/10
A recent insider trading cluster at Jazz Pharmaceuticals includes a significant open-market sale by
Mar 9, 2026
NEUTRAL
CLUSTER
4/10
Jazz Pharmaceuticals insiders executed a mix of open-market sales and non-cash equity transactions o
Mar 4, 2026
BULLISH
8-K
7/10
Jazz Pharmaceuticals reported strong 2025 financial results with $4.3 billion in revenue (+5% YoY) a
Feb 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (92% buy). Based on 24 analysts: 8 strong buy, 14 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$249.67 mean target
+3.9% upside
Hold (1.56)
$196.00 Low
$307.00 High
| Metric | Value |
|---|---|
| Current Price | $240.20 |
| Target Low | $196.00 |
| Target Mean | $249.67 |
| Target Median | $247.50 |
| Target High | $307.00 |
| # Analysts | 18 |
| Recommendation | Hold (1.56) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$6.17 | $5.53 | $7.07 | 174.7% | +2.1% | 8↑ 4↓ | $1.1B | 6.3% | 16 |
| Next Q 2026-09-30 |
$6.36 | $5.85 | $6.71 | -21.8% | -0.9% | 5↑ 7↓ | $1.2B | 2.4% | 16 |
| Current FY 2026-12-31 |
$25.22 | $24.38 | $26.99 | 200.9% | +4.4% | 10↑ 2↓ | $4.5B | 5.3% | 14 |
| Next FY 2027-12-31 |
$25.55 | $22.53 | $30.25 | 1.3% | +1.6% | 10↑ 3↓ | $4.8B | 7.5% | 16 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $6.165 | |
| 7d ago | $6.121 | +0.045 |
| 30d ago | $6.040 | +0.126 |
| 60d ago | $5.953 | +0.213 |
| 90d ago | $5.438 | +0.728 |
11 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 19, 2026 | UBS | UPGRADE | Neutral | Buy |
| May 6, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| May 6, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 6, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 6, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 22, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Apr 20, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 19, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 27, 2026 | Barclays | INITIATE | — | Overweight |
| Feb 25, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 25, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Feb 25, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 25, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Jan 12, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 12, 2026 | Needham | MAINTAIN | Buy | Buy |
| Dec 10, 2025 | Piper Sandler | REITERATE | Overweight | Overweight |
| Nov 24, 2025 | UBS | DOWNGRADE | Buy | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 8 | 14 | 2 | 0 | 0 | 92% | |
| Apr 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% | |
| Mar 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% | |
| Feb 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% | |
| Jan 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Aug 25, 2026
fda_pdufa
PDUFA: JAZZ — zanidatamab in HER2+ 1L advanced gastroesophageal adenocarcinoma — 2026-08-25
FDA target action date 2026-08-25 for JAZZ (Jazz Pharmaceuticals plc). Drug: zanidatamab. Indication: HER2+ 1L advanced gastroesophageal adenocarcinom
May 19, 2026
short_volume
Short Volume: JAZZ — 80.2% short (0.6M / 0.8M)
Short: 607,877 | Exempt: 1,095 | TRF Vol: 757,754 | Short Ratio: 80.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: JAZZ — 77.3% short (0.6M / 0.7M)
Short: 566,368 | Exempt: 0 | TRF Vol: 732,693 | Short Ratio: 77.3% | Off-exchange volume (dark pool + OTC)
May 5, 2026
earnings_calendar
JAZZ Q1 2026 Earnings Scheduled — 2026-05-05
May 5, 2026
short_volume
Short Volume: JAZZ — 72.1% short (0.4M / 0.5M)
Short: 387,875 | Exempt: 30,424 | TRF Vol: 538,087 | Short Ratio: 72.1% | Off-exchange volume (dark pool + OTC)
May 4, 2026
Clinical Trial
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Phase Phase 3 — ACTIVE_NOT_RECRUITING
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Zanidatamab (Phase 3)
Trial: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastri
May 2, 2026
clinical_trial_readout
T-90d Trial Readout: Zanidatamab (Phase 3)
Trial: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastri
Apr 27, 2026
short_volume
Short Volume: JAZZ — 57.9% short (0.4M / 0.7M)
Short: 413,856 | Exempt: 0 | TRF Vol: 715,069 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
dark_pool
Dark Pool: JAZZ — 1.0M shares, 29,415 trades
Week starting 2026-04-27. Total ATS volume: 983,862 shares across 29,415 trades.
Apr 23, 2026
short_volume
Short Volume: JAZZ — 63.2% short (0.4M / 0.6M)
Short: 401,110 | Exempt: 669 | TRF Vol: 634,749 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
Apr 22, 2026
short_volume
Short Volume: JAZZ — 80.9% short (0.6M / 0.7M)
Short: 553,943 | Exempt: 197,600 | TRF Vol: 685,111 | Short Ratio: 80.9% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: JAZZ — 76.7% short (0.4M / 0.6M)
Short: 442,695 | Exempt: 34,400 | TRF Vol: 577,197 | Short Ratio: 76.7% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
dark_pool
Dark Pool: JAZZ — 1.3M shares, 31,059 trades
Week starting 2026-04-20. Total ATS volume: 1,313,246 shares across 31,059 trades.
Apr 16, 2026
short_volume
Short Volume: JAZZ — 93.7% short (1.5M / 1.6M)
Short: 1,545,343 | Exempt: 260 | TRF Vol: 1,648,860 | Short Ratio: 93.7% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
short_volume
Short Volume: JAZZ — 61.4% short (0.3M / 0.5M)
Short: 311,647 | Exempt: 16,748 | TRF Vol: 507,557 | Short Ratio: 61.4% | Off-exchange volume (dark pool + OTC)
Jun 15, 2020
FDA
ZEPZELCA